SG11201506886TA - Monoclonal antibodies against antithrombin beta complexed with heparin - Google Patents

Monoclonal antibodies against antithrombin beta complexed with heparin

Info

Publication number
SG11201506886TA
SG11201506886TA SG11201506886TA SG11201506886TA SG11201506886TA SG 11201506886T A SG11201506886T A SG 11201506886TA SG 11201506886T A SG11201506886T A SG 11201506886TA SG 11201506886T A SG11201506886T A SG 11201506886TA SG 11201506886T A SG11201506886T A SG 11201506886TA
Authority
SG
Singapore
Prior art keywords
heparin
monoclonal antibodies
antibodies against
complexed
against antithrombin
Prior art date
Application number
SG11201506886TA
Inventor
Ye Jin
John E Murphy
Terry Hermiston
Timothy Myles
Frank Dittmer
Michael Strerath
Uwe Gritzan
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506886T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of SG11201506886TA publication Critical patent/SG11201506886TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201506886TA 2013-03-14 2014-03-14 Monoclonal antibodies against antithrombin beta complexed with heparin SG11201506886TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784590P 2013-03-14 2013-03-14
PCT/US2014/029541 WO2014153195A1 (en) 2013-03-14 2014-03-14 Monoclonal antibodies against antithrombin beta complexed with heparin

Publications (1)

Publication Number Publication Date
SG11201506886TA true SG11201506886TA (en) 2015-09-29

Family

ID=50680168

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506886TA SG11201506886TA (en) 2013-03-14 2014-03-14 Monoclonal antibodies against antithrombin beta complexed with heparin

Country Status (18)

Country Link
US (4) US9908942B2 (en)
EP (1) EP2970500A1 (en)
JP (1) JP2016519081A (en)
KR (1) KR20150127202A (en)
CN (1) CN105229033B (en)
AR (1) AR095499A1 (en)
AU (1) AU2014236198A1 (en)
BR (1) BR112015021399A2 (en)
CA (1) CA2916421A1 (en)
HK (1) HK1215261A1 (en)
MX (1) MX2015012441A (en)
PE (1) PE20160533A1 (en)
RU (1) RU2015143696A (en)
SG (1) SG11201506886TA (en)
TW (1) TW201529602A (en)
UY (1) UY35457A (en)
WO (1) WO2014153195A1 (en)
ZA (1) ZA201507628B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35457A (en) * 2013-03-14 2014-10-31 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAINST ANTITROMBIN ß
WO2015176738A1 (en) * 2014-05-19 2015-11-26 Nokia Solutions And Networks Oy Re-establishment procedure in dual connectivity networks
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CA2997801A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
EP3430059A1 (en) * 2016-03-18 2019-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578253A (en) 1978-12-11 1980-06-12 Teikoku Hormone Mfg Co Ltd Immune measurement of hito antithrombin 3
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
BE896543A (en) 1983-04-22 1983-08-16 Wallone Region Mono:clonal antibody systems against blood clotting proteins - comprising antibodies against antithrombin, anti:plasmin and antitrypsin
JPH0644876B2 (en) 1985-12-13 1994-06-15 株式会社ヤトロン Antithrombin / antithrombin 3 complex monoclonal antibody, method for producing the same, immunoassay method for thrombin / antithrombin 3 complex using the same, and method for purifying thrombin / antithrombin 3 complex using the same
JPH0266458A (en) 1988-09-01 1990-03-06 Takara Shuzo Co Ltd Method for measuring vitronectin and vitronectin-thrombin-antithrombin iii complex
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU628960B2 (en) 1989-04-07 1992-09-24 Teijin Limited Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JPH0694713A (en) * 1991-07-31 1994-04-08 Masashi Funayama Method for measuring antithrombin iii activity and measurement kit of antithrombin iii activity using it
JPH07238099A (en) * 1994-02-25 1995-09-12 Dai Ichi Pure Chem Co Ltd Nonoclonal antibody and method for immunoassay using the same
FR2718849B1 (en) 1994-04-14 1996-06-14 Pasteur Sanofi Diagnostics Method of immunoassay of antithrombin III activated by a glycosaminoglycan, corresponding monoclonal antibodies and their method of obtaining.
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JP3841364B2 (en) 1994-10-18 2006-11-01 株式会社三菱化学ヤトロン Anti-human vitronectin / thrombin / antithrombin III complex monoclonal antibody, hybridoma, and immunological assay
EP0912738B1 (en) 1996-05-22 2008-07-30 Viventia Biotech Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
EP0912728A1 (en) 1996-05-31 1999-05-06 MediGene Aktiengesellschaft Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
WO2000069256A1 (en) 1999-05-13 2000-11-23 Genzyme Transgenics Corp. Transgenically produced antithrombin iii and mutants thereof
JP2001321167A (en) 2000-05-10 2001-11-20 Cosmo Research Inst Monoclonal antibody
ES2609016T3 (en) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Antibodies that bind immunospecifically to BLyS
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
JP2002316999A (en) 2001-04-17 2002-10-31 Dai Ichi Pure Chem Co Ltd Monoclonal antibody
US20090226429A1 (en) 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
WO2005016236A2 (en) 2003-05-06 2005-02-24 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1499353A4 (en) 2002-04-15 2006-04-05 Human Genome Sciences Inc Antibodies that specifically bind to tl5
US7482139B2 (en) 2002-05-31 2009-01-27 University Of Utah Research Foundation Variants of antithrombin III
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
RU2262109C2 (en) 2002-12-30 2005-10-10 Институт биохимической физики им. Н.М. Эмануэля Российской академии наук Method for determination of blood plasma antithrombin iii concentration
DE602004025332D1 (en) 2003-03-14 2010-03-18 Wyeth Corp ANTIBODY TO IL21 RECEPTOR AND ITS USE
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
KR101225463B1 (en) 2003-11-07 2013-01-24 임뮤넥스 코포레이션 Antibodies that bind interleukin-4 receptor
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
JP4829609B2 (en) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 Human antibody enzyme and production method thereof
WO2006084050A2 (en) 2005-02-01 2006-08-10 Dyax Corp. Libraries and methods for isolating antibodies
JP2010533684A (en) 2007-07-20 2010-10-28 ユニベルシテ パリ サッド １１ Use of mutant antithrombin for the treatment or prevention of blood coagulation abnormalities
CA2696263C (en) 2007-08-15 2017-06-13 Bing Liu Monospecific and multispecific antibodies and method of use
MX2010005947A (en) 2007-11-29 2010-09-10 Talecris Biotherapeutics Inc Recombinantly modified plasmin.
ES2346618B1 (en) 2008-08-14 2011-08-03 Universidad De Murcia ANTIBODY MONOCLONAL ANTI ANTHROMBIN HUMAN CITRULINATED AND ITS USES.
NO330078B1 (en) 2008-09-22 2011-02-14 Optipro As Method and apparatus for monitoring wear in screen cloths
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
AR079944A1 (en) 2010-01-20 2012-02-29 Boehringer Ingelheim Int NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT
EP2614084A4 (en) 2010-09-09 2014-02-19 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140356377A1 (en) * 2011-08-25 2014-12-04 Umc Utrecht Holding B.V. Compounds for use in boosting coagulation
WO2013071138A1 (en) 2011-11-11 2013-05-16 Sio2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS
UY35457A (en) * 2013-03-14 2014-10-31 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAINST ANTITROMBIN ß
JP6094713B1 (en) 2016-06-30 2017-03-15 富士ゼロックス株式会社 Fixing member, fixing device, and image forming apparatus

Also Published As

Publication number Publication date
BR112015021399A2 (en) 2017-07-18
US9908942B2 (en) 2018-03-06
MX2015012441A (en) 2016-08-08
AU2014236198A1 (en) 2015-10-15
HK1215261A1 (en) 2016-08-19
CN105229033A (en) 2016-01-06
CN105229033B (en) 2019-04-23
PE20160533A1 (en) 2016-06-09
RU2015143696A (en) 2017-04-19
US20160024222A1 (en) 2016-01-28
US20140271661A1 (en) 2014-09-18
US10144784B2 (en) 2018-12-04
JP2016519081A (en) 2016-06-30
US9593166B2 (en) 2017-03-14
AR095499A1 (en) 2015-10-21
US20140271660A1 (en) 2014-09-18
US20180244799A1 (en) 2018-08-30
UY35457A (en) 2014-10-31
KR20150127202A (en) 2015-11-16
EP2970500A1 (en) 2016-01-20
TW201529602A (en) 2015-08-01
WO2014153195A1 (en) 2014-09-25
ZA201507628B (en) 2017-11-29
CA2916421A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti-fcrh5 antibodies
EP3083698A4 (en) Monoclonal anti-tk1 antibodies
GB201322583D0 (en) Antibodies
DK3071595T3 (en) HUMANIZED ANTI-CALLICINE-2 ANTIBODY
HK1215261A1 (en) Monoclonal antibodies against antithrombin beta complexed with heparin
HK1220142A1 (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
HK1220207A1 (en) Humanized anti-n2 antibodies n2
IL245488A0 (en) Anti-ccl17 antibodies
HK1217340A1 (en) Monoclonal antibody directed against cxcr5 cxcr5
HK1215714A1 (en) Anti-() --methamphetamine monoclonal antibodies ()-
GB201318283D0 (en) Antibodies